7,650.00

+36.00

+0.47%

52,106.00

+188.00

+0.36%

28,802.50

+268.50

+0.94%

Russell 2000 Futures

2,839.30

+18.00

+0.64%

4.9290

-0.0600

-1.20%

19.42

+2.22

+12.91%

3,914.70

+15.80

+0.41%

78,591.16

+926.80

+1.19%

Crude Oil Dec 26

100.67

-3.45

-3.31%

US Private Equity

10,850.63

-82.20

-0.75%

NasdaqCM - Nasdaq Real Time Price USD

Aethlon Medical, Inc. (AEMD)

5.44 -0.08 (-1.45%)

At close: October 30 at 4:00:01 PM EDT

5.31 -0.13 (-2.39%)

After hours: October 30 at 4:38:37 PM EDT

Loading Chart for AEMD

Chart Range Bar

Interval:

In partnership with ChartIQ

Aethlon Medical Shares Surge Over 400% After Announcing North Immunology Merger

Aethlon Medical Shares Surge Over 400% After Announcing North Immunology Merger

North Immunology joins biotech reverse merger boom with Aethlon deal

North Immunology joins biotech reverse merger boom with Aethlon deal

Aethlon Medical & North Immunology Announce Merger to Advance Novel IL-13 x IL-18 Bispecific Antibody for Atopic Dermatitis

Aethlon Medical & North Immunology Announce Merger to Advance Novel IL-13 x IL-18 Bispecific Antibody for Atopic Dermatitis

Aethlon Medical Reports Q1 Fiscal 2027 Results and Progress on Hemopurifier® Program

Aethlon Medical Reports Q1 Fiscal 2027 Results and Progress on Hemopurifier® Program

Aethlon Medical Continues to Observe Directional Changes in Second Cohort of Australian Oncology Clinical Trial Evaluating Hemopurifier®

Aethlon Medical Continues to Observe Directional Changes in Second Cohort of Australian Oncology Clinical Trial Evaluating Hemopurifier®

Aethlon Medical Announces Pricing of $4.0 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules

Aethlon Medical Announces Pricing of $4.0 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules

Aethlon Medical Announces Publication Demonstrating Novel Long COVID Biomarker and Potential Therapeutic Target for the Hemopurifier®

Aethlon Medical Announces Publication Demonstrating Novel Long COVID Biomarker and Potential Therapeutic Target for the Hemopurifier®

Aethlon Medical advances Hemopurifier study as final trial cohort nears completion

Aethlon Medical advances Hemopurifier study as final trial cohort nears completion

Aethlon Medical Inc (AEMD) Q4 2026 Earnings Call Highlights: Strategic Advances Amid Financial ...

Aethlon Medical Inc (AEMD) Q4 2026 Earnings Call Highlights: Strategic Advances Amid Financial ...

Aethlon (AEMD) Q4 2026 Earnings Transcript

Aethlon (AEMD) Q4 2026 Earnings Transcript

Aethlon Medical Announces Fiscal Year End March 31, 2026 Financial Results and Corporate Update

Aethlon Medical Announces Fiscal Year End March 31, 2026 Financial Results and Corporate Update

Mobilize your Website

View Site in Mobile | Classic

Share by: